Frédéric Gaudette

Discovery of <i>N</i>-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor

Nancy Zhou, Oscar Moradei, Stéphane Raeppel et al. · Journal of Medicinal Chemistry · 2008 · 108 citations · Full text

Compound 8, Chemoprevention Strategy, Pharmacotherapy +18

Lewis acid-catalyzed Mannich type reactions with potassium organotrifluoroborates

Jean‐Philipe Tremblay‐Morin, Stéphane Raeppel, Frédéric Gaudette · Tetrahedron Letters · 2004 · 58 citations

Cross-coupling Reaction, Engineering, Potassium Organotrifluoroborates +4

N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors

Michael R. Mannion, Stéphane Raeppel, Stephen Claridge et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 50 citations · Full text

Medicinal Chemistry, Drug Target, Novel Series +12

Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors

Isabelle Paquin, Stéphane Raeppel, Silvana Leit et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 35 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Bioorganic Chemistry +11

N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors

Stéphane Raeppel, Stephen Claridge, Oscar Saavedra et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 34 citations · Full text

Medicinal Chemistry, Drug Target, Novel Series +11